Tysabri and PML in Georgia: Understanding Symptoms and Diagnosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Exposure Risk

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, distinguishing early PML signs from other conditions is critical. Decades of pharmacovigilance have established a clear framework for monitoring this rare but serious brain infection. This page explains the key symptoms, diagnostic steps, and what Georgia patients need to know.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed through brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes, though many patients still suffer permanent disability or death.

Pharmacological Mechanism and Risk Factors

The pharmacological mechanism linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents immune cells from crossing the blood-brain barrier, thereby reducing inflammatory activity in the central nervous system. However, this immunosuppressive effect also impairs immune surveillance against JC virus, allowing latent virus to reactivate and cause PML. The FDA-approved labeling identifies three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning clearly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML, withholding the drug immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers and patients were adequately informed about the magnitude of PML risk, particularly in the context of evolving knowledge about risk factors.

Statute of Limitations for Tysabri Claims in Georgia

For affected patients in Georgia, attorney-related considerations are important. The statute of limitations for personal injury claims in Georgia is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, the timeline between exposure and documented harm can be prolonged. PML may develop months to years after starting Tysabri, and symptoms can be subtle initially, delaying diagnosis. The FDA labeling notes that the duration of treatment prior to onset of herpes-related infections ranged from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and similar variability applies to PML. This latency period can complicate the determination of when the statute of limitations begins to run. In Georgia, the "discovery rule" may apply, meaning the clock starts when the plaintiff knew or should have known of the injury and its possible cause. Consulting with an attorney experienced in pharmaceutical litigation is essential to assess individual circumstances and ensure timely filing.

Legal Recourse and Patient Considerations

The risk of PML is a serious consideration for any patient prescribed Tysabri. The drug's labeling emphasizes that physicians should weigh the expected benefit against the risk of PML when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the consequences are often devastating, and legal options may be available to seek compensation for medical expenses, lost income, and pain and suffering. However, the success of any claim depends on the specific facts, including the adequacy of warnings provided and the timing of diagnosis. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in the FDA-approved labeling. Patients in Georgia who have been harmed by PML should be aware of the statute of limitations and the importance of prompt legal consultation. The evidence underscores the need for careful monitoring and informed decision-making when using this medication.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, the discovery rule may apply, meaning the clock starts when the plaintiff knew or should have known of the injury and its possible cause. Given the latency period of PML, it is crucial to consult an attorney promptly.

What are the risk factors for developing PML while on Tysabri?

According to the FDA-approved labeling, the three key risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.